Photo by epSos.de, via Flickr
The FDA has recently approved a new drug, called Kadcyla, to treat individuals with late-stage breast cancer that is reportedly more effective and has fewer side effects.
Feb. 22, 2013 // Patients with HER2-positive breast cancer, a particularly aggressive form of breast cancer, now have a new, effective and less toxic therapeutic option.
On Friday, Feb., 22, the Food and Drug Administration (FDA) approved the new treatment drug, Kadcyla (trastuzumab emtansine), also known as TDM-1, which combines Traztuzumab, also called Herceptin, with the powerful chemotherapy drug emtansine.
The drug therapy is developed by Roche-owned Genentech, which funded the study.
Results from clinical trials of the drug TDM-1, known as “Super Herceptin,” showed that it was more effective and less toxic than the standard regimen for this type of tumor. The medication kept patients free of disease for longer than the standard chemo.